No results for ‘’
Venmax Drugs & Pharmaceuticals Ltd
₹23.96
(0.17%)
Mon, 25 May 2026, 11:44 am
Health Technology
Pharmaceuticals: Major
24.5KVenmax Drugs & Pharmaceuticals PE Ratio
No Result Found
| Particulars |
|---|
| Price to earnings ratio |
| Price to book ratio |
| Price to sales ratio |
| Price to cash flow ratio |
| Enterprise value |
| Enterprise value to EBITDA ratio |
| Debt to equity ratio |
| Return on equity % |
Venmax Drugs & Pharmaceuticals Ltd Price to Earnings Ratio
The Venmax Drugs & Pharmaceuticals Ltd Price to Earnings Ratio is a key financial metric used by investors to evaluate Venmax Drugs & Pharmaceuticals Ltd's valuation, profitability, and overall financial performance. Tracking the Venmax Drugs & Pharmaceuticals Ltd Price to Earnings Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Venmax Drugs & Pharmaceuticals Ltd (NSE: , BSE: 531015) is currently trading at ₹23.96, with a market capitalization of ₹0. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Venmax Drugs & Pharmaceuticals Ltd Price to Earnings Ratio is essential for fundamental analysis.
Venmax Drugs & Pharmaceuticals Ltd Price to Earnings Ratio Current Value
The current Venmax Drugs & Pharmaceuticals Ltd Price to Earnings Ratio stands at 0.
The Venmax Drugs & Pharmaceuticals Ltd Price to Earnings Ratio remains stable, indicating consistent financial performance.
Venmax Drugs & Pharmaceuticals Ltd Price to Earnings Ratio Historical Trend
The Venmax Drugs & Pharmaceuticals Ltd Price to Earnings Ratio has shown the following historical trend:
The decline in Venmax Drugs & Pharmaceuticals Ltd Price to Earnings Ratio indicates improving financial efficiency or better earnings growth.
What Venmax Drugs & Pharmaceuticals Ltd Price to Earnings Ratio Indicates for Investors
The Venmax Drugs & Pharmaceuticals Ltd Price to Earnings Ratio plays a crucial role in understanding the company's financial health and valuation.
A higher P/E ratio indicates investors expect strong future earnings growth, while a lower ratio may signal undervaluation.
Venmax Drugs & Pharmaceuticals Ltd Price to Earnings Ratio Analysis Summary
The Venmax Drugs & Pharmaceuticals Ltd Price to Earnings Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Venmax Drugs & Pharmaceuticals Ltd Price to Earnings Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Venmax Drugs & Pharmaceuticals Ltd Price to Earnings Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.